Information on shares, voting rights and authorized capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailAfter acquiring its own shares on 28 January 2025, Šiaulių Bankas AB (hereinafter - the Bank) pursuant to Article 19(2) of the Law on Securities of the Republic of Lithuania provides information on the total number of voting rights granted by the shares issued by it and the amount of the authorized capital, the number of shares and their nominal value:
| Type of shares | Ordinary registered shares |
| ISIN code | LT0000102253 |
| Bank’s LEI code | 549300TK038P6EV4YU51 |
| Nominal value of 1 share, EUR | 0.29 |
| Number of shares, units | 662 996 646 |
| Authorised capital, EUR | 192 269 027,34 |
| Number of votes granted by all issued shares, units | 662 996 646 |
| Number of votes calculating the quorum of the General Meeting of Shareholders | 650 653 783 |
Additional information:
Tomas Varenbergas
Head of Investment Management Division
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
